Patient Derived Models to Study Head and Neck Cancer Radiation Response.
cancer
head and neck cancer
patient-derived models
radiation
radiation therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Feb 2020
12 Feb 2020
Historique:
received:
18
01
2020
revised:
08
02
2020
accepted:
09
02
2020
entrez:
16
2
2020
pubmed:
16
2
2020
medline:
16
2
2020
Statut:
epublish
Résumé
Patient-derived model systems are important tools for studying novel anti-cancer therapies. Patient-derived xenografts (PDXs) have gained favor over the last 10 years as newer mouse strains have improved the success rate of establishing PDXs from patient biopsies. PDXs can be engrafted from head and neck cancer (HNC) samples across a wide range of cancer stages, retain the genetic features of their human source, and can be treated with both chemotherapy and radiation, allowing for clinically relevant studies. Not only do PDXs allow for the study of patient tissues in an in vivo model, they can also provide a renewable source of cancer cells for organoid cultures. Herein, we review the uses of HNC patient-derived models for radiation research, including approaches to establishing both orthotopic and heterotopic PDXs, approaches and potential pitfalls to delivering chemotherapy and radiation to these animal models, biological advantages and limitations, and alternatives to animal studies that still use patient-derived tissues.
Identifiants
pubmed: 32059418
pii: cancers12020419
doi: 10.3390/cancers12020419
pmc: PMC7072508
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NIDCR NIH HHS
ID : P50 DE026787
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA076917
Pays : United States
Organisme : NIH HHS
ID : CA014520
Pays : United States
Organisme : American Cancer Society
ID : RSG-16-091-01-TBG
Organisme : NIH HHS
ID : P50DE026787
Pays : United States
Références
J Transl Med. 2021 Apr 28;19(1):180
pubmed: 33910584
PLoS One. 2012;7(8):e44219
pubmed: 22937164
Ann Oncol. 2017 Oct 01;28(10):2595-2605
pubmed: 28945830
Biom J. 2005 Jun;47(3):358-68
pubmed: 16053259
Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1137-46
pubmed: 19917928
Ann Transl Med. 2016 Dec;4(23):461
pubmed: 28090517
Nature. 2015 Feb 19;518(7539):422-6
pubmed: 25470049
Cancer Res. 2013 Aug 1;73(15):4791-800
pubmed: 23749640
FASEB J. 2018 Mar;32(3):1537-1549
pubmed: 29146734
Cancer. 1952 Jan;5(1):24-44
pubmed: 14886896
Clin Cancer Res. 2011 Jan 1;17(1):134-41
pubmed: 21081655
Oncogene. 2016 Jan 21;35(3):290-300
pubmed: 25893296
Nat Med. 2011 Oct 23;17(11):1514-20
pubmed: 22019887
J Vis Exp. 2019 Apr 22;(146):
pubmed: 31058896
Phys Med Biol. 2011 Apr 21;56(8):2585-99
pubmed: 21444969
Mol Cancer Ther. 2017 Jul;16(7):1257-1268
pubmed: 28446642
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1591-9
pubmed: 18640502
Cancer Treat Rev. 2015 Feb;41(2):105-13
pubmed: 25579753
Sci Rep. 2019 Aug 28;9(1):12480
pubmed: 31462653
Radiat Oncol. 2014 Sep 19;9:207
pubmed: 25234922
Oral Oncol. 2018 Dec;87:49-57
pubmed: 30527243
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
Clin Cancer Res. 2013 Feb 15;19(4):855-64
pubmed: 23251001
Cancer Discov. 2014 Sep;4(9):998-1013
pubmed: 25185190
Cancer Discov. 2014 Mar;4(3):280-91
pubmed: 24550033
J Immunol. 2005 May 15;174(10):6477-89
pubmed: 15879151
Blood. 2005 Sep 1;106(5):1565-73
pubmed: 15920010
Blood. 2002 Nov 1;100(9):3175-82
pubmed: 12384415
Cell Oncol (Dordr). 2011 Dec;34(6):511-21
pubmed: 21681527
Cell. 2019 Jun 13;177(7):1903-1914.e14
pubmed: 31031007
Eur J Cancer (1965). 1967 Nov;3(4):315-9
pubmed: 6078931
Br J Cancer. 1974 Jan;29(1):97
pubmed: 4856576
J Clin Med. 2019 Nov 05;8(11):
pubmed: 31694307
Clin Cancer Res. 2019 Sep 1;25(17):5376-5387
pubmed: 31175091
Nat Commun. 2017 Sep 27;8(1):707
pubmed: 28955032
Stem Cell Reports. 2018 Apr 10;10(4):1175-1183
pubmed: 29576539
Transl Oncol. 2016 Feb;9(1):46-56
pubmed: 26947881
Curr Genomics. 2007 Sep;8(6):360-9
pubmed: 19412436
JAMA Oncol. 2015 Dec;1(9):1325-32
pubmed: 26270858
Br J Cancer. 2014 Sep 23;111(7):1305-9
pubmed: 25117813
J Natl Cancer Inst. 2013 Jan 2;105(1):11-24
pubmed: 23231975
Sci Signal. 2017 Jan 03;10(460):
pubmed: 28049763
Genome Med. 2019 Jun 20;11(1):40
pubmed: 31221199
Med Phys. 2001 Jun;28(6):868-93
pubmed: 11439485
J Clin Oncol. 2012 Feb 1;30(4):e45-8
pubmed: 22184402
Curr Protoc Immunol. 2008 May;Chapter 15:15.21.1-15.21.21
pubmed: 18491294
Med Phys. 2011 Dec;38(12):6754-62
pubmed: 22149857
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Sep 5;776(2):231-6
pubmed: 12138005
Breast Cancer Res. 2018 Sep 5;20(1):108
pubmed: 30185216
Clin Cancer Res. 2017 Oct 15;23(20):6044-6053
pubmed: 28659312
Eur J Cancer Clin Oncol. 1985 Jul;21(7):845-51
pubmed: 4043172
Biochem Pharmacol. 2014 Sep 15;91(2):135-43
pubmed: 24950467
PLoS One. 2014 Jun 26;9(6):e100995
pubmed: 24967635
Laryngoscope. 2017 Dec;127(12):2777-2783
pubmed: 28561270
Immunol Today. 1992 Jun;13(6):219-24
pubmed: 1627250
J Comp Pathol. 2015 Feb-Apr;152(2-3):238-42
pubmed: 25670669
Clin Cancer Res. 2010 Mar 1;16(5):1442-51
pubmed: 20179238
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8234-E8243
pubmed: 28835536
Int J Cancer. 2020 Jul 15;147(2):472-477
pubmed: 31359406
Radiat Oncol. 2012 Dec 27;7:223
pubmed: 23270380
J Exp Med. 2011 Apr 11;208(4):653-61
pubmed: 21464223
Oncotarget. 2014 Oct 15;5(19):9281-94
pubmed: 25238142
Cell Rep. 2018 Oct 30;25(5):1318-1331.e4
pubmed: 30380421
Phys Med Biol. 2011 Jun 21;56(12):R55-83
pubmed: 21617291
Nat Immunol. 2019 Jul;20(7):770-774
pubmed: 31160798
Oral Oncol. 2017 Jan;64:65-72
pubmed: 28024726
Cancer Chemother Pharmacol. 1990;26(3):205-9
pubmed: 2357768
Med Phys. 2012 Jun;39(6Part11):3724
pubmed: 28517140
Mol Cancer Ther. 2011 Aug;10(8):1311-6
pubmed: 21673092